Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)

Metastatic disease is a major morbidity of prostate cancer (PCa). Its prevention is an important goal. To assess the effect of screening for PCa on the incidence of metastatic disease in a randomized trial. Data were available for 76 813 men aged 55–69 yr coming from four centers of the European Randomized Study of Screening for Prostate Cancer (ERSPC). The presence of metastatic disease was evaluated by imaging or by prostate-specific antigen...